700 patients109,892 observations180 daysLIVE

Patient P-02311

Synthetic patientMETA-24 · Day 143 · 45–54 · F · baseline S02Steering view · 3DOpen companion preview
Is the drug working?

Metabolic response 83 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 82%, metabolic response 81 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: nausea / gi symptoms 21, tolerability burden 20, no drift from the model.

Still taking it?

53 of 61 scheduled doses in the last 60 days are biologically confirmed (87%); 5 were logged but show no dose signature. Dose signature: resting HR +3 bpm, HRV −10 ms.

last 10 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 150Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • 💊Take the dose at the same time relative to your evening meal
  • 💊No additional supplements this week
Adherence
84% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-02311 is on day 143 of META-24 (SR, baseline S02): response improving, tolerance favorable, GI favorable. Over 14 days response moved +8 and GI -1; discontinuation risk is 18%. The state is in the restoration basin, heading towards restoration.

Biology sets the gain: FUT2 non-secretor, Poor metabolizer; butyrate capacity 80/100, diversity 3.7. Pushing it down: Escherichia coli 6.912% (LPS load) (-26.9), Poor metabolizer (-24.4), FUT2 non-secretor (-20.4). Pulling it up: Protein (supports) (+17.5), Butyrate producers intact (+14.3). From the daily log: protein -4.1 GI next day, simple carbs -2.9 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Improving
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Deteriorating
Nutritional resilience
Favorable
Discontinuation risk
18%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (daily oral dose, morning)
  1. Day 0 META-24 startedBaseline state S02

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • Inflammatory activity+9
  • Toxicity+3
  • Nutritional resilience-2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Glucose, CGM daily mean
    CGM
    140 mg/dL
    stable · +0.4 vs previous 14 d
    Active minutes
    Wearable
    41 min
    worsening · -1.9 vs previous 14 d
    Sleep duration
    Wearable
    6.1 h
    stable · -0.0 vs previous 14 d
    Energy level
    Daily log
    6.2/10
    worsening · -0.3 vs previous 14 d
    Steps
    Wearable
    4,020
    stable · -64 vs previous 14 d
    GI burden
    Companion
    21.1/100
    worsening · +4.5 vs previous 14 d
    Adherence
    Companion
    83.9 %
    stable · +0.6 vs previous 14 d
    This trajectory is doing well — what to keep, what to watch
    Steering view →

    Heading towards restoration · 83 from the failing basin, 9 from restoration.

    Good elements to keep
    • Protein (supports)
      perturbation · steering +17.5
    • Butyrate producers intact
      hidden · steering +14.3
    • Simple carbohydrates (supports)
      perturbation · steering +10.2
    • Protein
      supporter · GI -4.1 next day
    • Simple carbohydrates
      supporter · GI -2.9 next day
    Main detractors to watch
    • Escherichia coli 6.912% (LPS load)
      hidden · steering -26.9
    • Poor metabolizer
      hidden · steering -24.4
    • FUT2 non-secretor
      hidden · steering -20.4
    • Antibiotic course
      perturbation · steering -4.7
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -4.1supporter · 95%
    • Simple carbohydrates
      -2.9supporter · 70%
    • Dietary fat load
      +1no signal · 21%
    • Insoluble fibre
      +0.7no signal · 15%
    • Alcohol
      -0.4no signal · 15%
    • Ultra-processed food
      +0.1no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    24/100
    vs baseline (day 0)
    +4
    3 improved · 2 worsened
    synthetic signature · consistent with this patient's biology
    • 2 opportunists above range: Escherichia coli, Klebsiella pneumoniae
    • 1 keystone species absent
    • 2 resistance genes
    • Host DNA fragmentation atypical
    Pathogens / opportunists2/5
    from 3
    Keystone species1/8
    Diversity0/2
    Metabolic modules0/4
    Vitamin synthesis1/7
    Oral translocation0/1
    Host DNA1/1
    from 0
    Tissue recycling0/1
    Central mechanisms0/2
    Virulence factors1/1
    Antibiotic resistance genes2/2
    from 3
    Genetic predisposition2/2
    Opportunists above range
    Escherichia coli 6.912% AR
    Klebsiella pneumoniae 2.073% AR
    Keystone species absent
    Akkermansia muciniphila
    Capacity
    Shannon 3.43 · butyrate 800 CPM · SCFA 1313
    1 vitamins below
    Host & mechanisms
    host DNA fragmentation atypical
    tissue recycling 25/100
    oral translocation 1.61% AR
    2 resistance genes · 1 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 40
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • WearableSleep 6.1 h, below personal baseline
    • Drug metabolism and exposure 40
      • DNACYP2D6 poor metabolizer → higher exposure
    • Autonomic recovery 20
      • WearableShort sleep window
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    Microbiome
    Shannon diversity 3.7 · butyrate capacity 80/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    60 ms
    Sleep
    6.2 h
    Steps
    3,808
    Resting HR
    62 bpm
    Daily log: GI score 21, nutritional resilience 64, adherence 84.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Keep fibre steady; no new sources this week
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Log the daily check-in; one line is enough
    • A 15-minute walk after lunch
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0207149%S0179
    P-0213647%S0178
    P-0231047%S01NP-02improved79
    P-0203345%S0173
    P-0223645%S0175
    P-0224045%S0182
    P-0201244%S0173
    P-0207944%S0175
    P-0225741%S0186
    P-0241241%S0176
    P-0259940%S01SC-12improved83
    P-0234039%S0184